Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.
09.10.2023 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug . Seite 1
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lowered by equities research analysts at Morgan Stanley from $210.00 to $175.00 in a note issued to investors on Monday, FlyOnTheWall reports. Morgan Stanley’s target price would suggest a potential upside of 3.97% from the stock’s previous close. ALNY has been the subject of […]
Allspring Global Investments Holdings LLC decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 18.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,889 shares of the biopharmaceutical company’s stock after selling 6,492 shares during the period. Allspring Global Investments Holdings […]